WaveMan · Company
PBSV · Pharma-Bio Serv, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PBSV Pharma-Bio Serv (PBSV) Insider Trading, Ownership & Congress Trades

Services · Services-management consulting services · CIK 0001304161
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-5.3%
XBRL, annual
Net margin
-1.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$9.5M
four quarters, 2025-08-01 to 2026-07-31
History
FY Oct 2025$9.0M
FY Oct 2024$9.5M
FY Oct 2023$17.0M
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026$2.3M
Apr 2026$2.7M
Jan 2026$2.3M
Oct 2025$2.1M
Jul 2025$2.0M
Apr 2025$2.4M
Jan 2025$2.5M
Oct 2024$2.3M
At each fiscal year end
Single quarter
Net margin, TTM
+2.7%
net income over revenue, 2025-08-01 to 2026-07-31
History
FY Oct 2025-1.1%
FY Oct 2024-8.2%
FY Oct 2023+7.7%
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026-0.6%
Apr 2026+8.6%
Jan 2026+1.4%
Oct 2025-0.0%
Jul 2025-10.4%
Apr 2025+3.9%
Jan 2025+0.3%
Oct 2024+0.7%
At each fiscal year end
Single quarter
Free cash flow, TTM
-$421.4K
operating cash flow minus capex, 2025-08-01 to 2026-07-31
History
FY Oct 2025-$221.5K
FY Oct 2024-$726.4K
FY Oct 2023$1.9M
FY Oct 2022$573.2K
FY Oct 2021$794.0K
Jul 2026$59.5K
Apr 2026-$367.6K
Jan 2026-$392.6K
Oct 2025$279.3K
Jul 2025$234.5K
Apr 2025-$305.8K
Jan 2025-$429.5K
Oct 2024-$78.6K
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
History
FY Oct 2025n/a
FY Oct 2024n/a
FY Oct 2023n/a
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
History
FY Oct 2025n/a
FY Oct 2024n/a
FY Oct 2023n/a
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+2.2%
TTM net income over average of 2025-07-31 and 2026-07-31
History
FY Oct 2025-0.8%
FY Oct 2024-5.2%
FY Oct 2023+8.0%
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026+2.2%
Apr 2026+0.5%
Jan 2026-0.7%
Oct 2025-0.8%
Jul 2025-0.7%
Apr 2025-1.5%
Jan 2025-3.8%
Oct 2024-5.2%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.0%
TTM net income over average of 2025-07-31 and 2026-07-31
History
FY Oct 2025-0.7%
FY Oct 2024-4.3%
FY Oct 2023+6.5%
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026+2.0%
Apr 2026+0.5%
Jan 2026-0.5%
Oct 2025-0.7%
Jul 2025-0.6%
Apr 2025-1.2%
Jan 2025-2.8%
Oct 2024-4.3%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
History
FY Oct 2025n/a
FY Oct 2024n/a
FY Oct 2023n/a
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.4%
operating income (EBIT proxy) over average of 2025-07-31 and 2026-07-31 minus current liabilities
History
FY Oct 2025-4.8%
FY Oct 2024-8.0%
FY Oct 2023+6.2%
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026-1.4%
Apr 2026-3.5%
Jan 2026-5.6%
Oct 2025-4.8%
Jul 2025-5.0%
Apr 2025-5.4%
Jan 2025-6.7%
Oct 2024-8.0%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
48.00x
close 2026-10-09 over four quarters of diluted EPS, 2025-08-01 to 2026-07-31
History
FY Oct 2025n/a
FY Oct 2024n/a
FY Oct 2023n/a
FY Oct 2022n/a
FY Oct 2021n/a
Jul 202642.00x
Apr 2026250.00x
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
History
FY Oct 2025n/a
FY Oct 2024n/a
FY Oct 2023n/a
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.8%
TTM free cash flow over market value at close 2026-10-09
History
FY Oct 2025-1.8%
FY Oct 2024-5.5%
FY Oct 2023+9.7%
FY Oct 2022+2.9%
FY Oct 2021+3.3%
Jul 2026-4.4%
Apr 2026-2.2%
Jan 2026-1.4%
Oct 2025-1.8%
Jul 2025-4.1%
Apr 2025-14.1%
Jan 2025-13.7%
Oct 2024-5.5%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
History
FY Oct 2025n/a
FY Oct 2024n/a
FY Oct 2023n/a
FY Oct 2022n/a
FY Oct 2021n/a
Jul 2026n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

PBSV Stock Sonar score 3/7 axes

Find similar shapesCompare

PBSV ranks highest on risk and compliance (71st percentile) and profitability (44th), and lowest on growth (26th), among Services peers.

Profitability
44
Inputs
  • Return on equity+2.2% · 40 pct, sector of 209
  • Return on assets+2.0% · 55 pct, sector of 270
  • Return on invested capitalno debt line filed
  • Return on capital employed-1.4% · 36 pct, sector of 204
Growth
26
Inputs
  • Revenue growth, YoY-5.3% · 26 pct, sector of 343
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
71
Inputs
  • Short interest, % of float+0.0% · 90 pct, sector of 385
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+11.4% · 52 pct, sector of 228
4 not measured: Financial health, Insider conviction, Institutional and government, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-5.3% year over year
below 74% of Services
Margin
-1.1% net margin
below 61% of Services
Buybacks
$2.4K repurchased, FY to 2026-07-31
the lowest in Services
Short interest
<0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
the lowest in Services
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PBSV

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-20.3%12M
-42%-28%-14%+0%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
DASHABNBSEETSYFICOXMTRACNZGFLYWMAMAXPHR

Pharma-Bio Serv insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Pharma-Bio Serv, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns PBSV: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in PBSV

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PBSV planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Victor Sanchez
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$245.9K
$245.3K
$175.6K
-23%
n/a
2024
$245.9K
$241.2K
$181.9K
-26%
n/a
2023
$323.7K
$321.5K
$225.6K
-11%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-102024-102023-102022-10
Revenue$9.0M$9.5M$17.0M$19.4M
Gross profit$2.9M$2.5M$5.1M$4.9M
Operating income$-637.7K$-1.3M$1.1M$1.2M
Net income$-100.5K$-777.6K$1.3M$1.0M
EPS (diluted)-0.00-0.030.06n/a
Operating cash flow$-214.9K$-566.7K$1.9M$592.5K
Cashn/an/an/a$14.5M
Buybacks$31.4K$11.3K$34.3K$82.0K
Dividends paid$1.7M$1.7M$1.7M$3.4M
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies